These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21504557)

  • 21. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
    Shi FD; Zhang JY; Liu D; Rearden A; Elliot M; Nachtsheim D; Daniels T; Casiano CA; Heeb MJ; Chan EK; Tan EM
    Prostate; 2005 May; 63(3):252-8. PubMed ID: 15538718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.
    Leidinger P; Keller A; Milchram L; Harz C; Hart M; Werth A; Lenhof HP; Weinhäusel A; Keck B; Wullich B; Ludwig N; Meese E
    PLoS One; 2015; 10(6):e0128235. PubMed ID: 26039628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
    Wan XS; Xu YA; Ware JH; Kennedy AR
    Prostate; 2003 Jul; 56(2):131-41. PubMed ID: 12746838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Established oneself the detection of serum prostate specific antigen and application in clinical practice].
    Feng T; Dou CQ; Xia TL
    Zhonghua Wai Ke Za Zhi; 1994 Nov; 32(11):685-7. PubMed ID: 7539736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
    Dai L; Li J; Ortega R; Qian W; Casiano CA; Zhang JY
    J Immunol Res; 2014; 2014():827827. PubMed ID: 24860838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
    Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
    Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
    Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
    Onur R; Ilhan N; Orhan I; Ilhan N
    World J Urol; 2003 May; 21(1):43-7. PubMed ID: 12756494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
    Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
    Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
    Lee F; Littrup PJ; Loft-Christensen L; Kelly BS; McHugh TA; Siders DB; Mitchell AE; Newby JE
    Cancer; 1992 Jul; 70(1 Suppl):211-20. PubMed ID: 1376190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.